First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia AO Odibo, CC Rada, AG Cahill, KR Goetzinger, MG Tuuli, L Odibo, GA Macones and SK England OBJECTIVE: To compare the first-trimester serum concentrations of soluble fms-like tyrosine kinase-1 (sFlt-1), free vascular endothelial growth factor (free-VEGF), placental growth factor (PlGF), and uterine artery pulsatility index (PI) in women who later developed preeclampsia (PE). STUDY DESIGN: Prospectively collected maternal serum samples were evaluated for sFlt-1, free VEGF, and PlGF levels in 63 cases who later developed PE compared with 252 unaffected controls. Serum levels of these angiogenic factors were measured using Quantikine immunoassays. Both univariate and multivariate analyses were used to evaluate the association between angiogenic factors and PE. The relationship between the angiogenic factors and mean maternal uterine artery PI was also evaluated. RESULT: Maternal serum sFlt-1 levels were not significantly different between the cases and controls. Mean free-VEGF levels were significantly higher in women destined to develop PE compared with the controls (P ¼ 0.04), and mean PlGF levels were significantly lower in women who later developed PE (P ¼ 0.01). There was no significant correlation between maternal mean uterine artery PI and angiogenic factors evaluated. Receiver-operating characteristic curves revealed that none of the factors were clinically useful for prediction in the first trimester of PE. CONCLUSION: Despite some significant differences in the first-trimester serum levels of angiogenic factors, our models suggest that these factors are not clinically useful for prediction in women who later developed PE.
INTRODUCTION
Preeclampsia (PE) is an important cause of perinatal mortality and morbidity affecting 3% to 5% of pregnancies. 1, 2 Although the underlying etiology of PE is not fully elucidated, abnormal placentation and endothelial dysfunction are likely involved. One model proposes that failure of proper uterine artery remodeling by the placental trophoblasts results in hypoxic insults to the placenta and release of soluble fms-like tyrosine kinase-1 (sFlt-1). sFlt-1 is an antagonist of vascular endothelial growth factor (VEGF) and placental growth factors (PlGFs). Because VEGF and PlGF are important angiogenic factors, the model suggests that this antagonism deprives the maternal vascular endothelium of essential developmental factors, resulting in the syndrome of PE. 3, 4 Extensive evidence indicates that circulating levels of sFlt-1 are increased, whereas VEGF and PlGF are decreased during the second trimester in pregnant women who later develop PE. 5 Unfortunately, attempts to identify first-trimester angiogenic markers predictive of PE have yielded contradictory results. For example, although some studies have shown slightly increased levels of sFlt-1 in the first trimester, 6 others have shown decreased levels, 7, 8 and some have found no significant differences. 5, 9, 10 A large recent study analyzing several factors, including sFlt-1, VEGF, and PlGF, in low-risk pregnancies was unable to identify a clinically useful model to predict PE, 11 strongly indicating that a different approach may be required.
Because inadequate vascular remodeling during placentation reduces blood flow from the uterus to the placenta and increases vascular resistance, Doppler ultrasound measurements of uterine artery blood flow have been investigated as a possible method of firsttrimester PE prediction. Unfortunately, although such measurements have been shown to have some predictive value in high-risk pregnancies 12 or when compared between the first and second trimesters, 13 single measurements in the first trimester have not proven to be as clinically useful. 5, 11 Our objective was to explore the feasibility of using angiogenic markers in the first trimester to predict future development of PE. We analyzed the relationship between uterine pulsatility index (PI) and the serum concentrations of sFlt-1, free-VEGF, and PlGF in women who later developed PE compared with a group with uncomplicated pregnancies.
METHODS
This is a nested case-control study within a study involving prospectively enrolled subjects in a first-trimester screening program for adverse pregnancy outcomes.
14 Approval for the study was obtained from the Institutional Review Board of Washington University School of Medicine in St Louis, MO, USA, and all women gave written informed consent. Women with singleton pregnancies between 11 and 14 weeks' gestation attending for first-trimester aneuploidy screening were approached to participate in the study from December 2009 to March 2012. Gestational age was calculated from the last menstrual period and confirmed by crown-rump length measurement.
Cases were defined as patients who developed PE at any gestational age. PE was defined using guidelines from the American College of Obstetricians and Gynecologist. 15 These were compared with a control group without any adverse pregnancy outcome followed over the same period, matched for gestational age ± 3 days at sampling with a ratio of 1 case to 4 controls.
Maternal serum analytes
Each patient provided approximately 10 cc of maternal blood, which was drawn by venipuncture into non-heparinized tubes. The blood samples were allowed to clot and then centrifuged at 1500 g for 15 min. The serum was removed, and aliquots were stored at À 80 1C until analyzed.
Serum sFlt-1, free-VEGF, and PlGF levels were measured using enzymelinked immunoassay technique using Quantikine immunoassay (R&D Systems Europe Ltd, Abington, UK). The lower limits of detection of the assays were 15 pg ml À 1 for sFlt-1, 5 pg ml À 1 for VEGF, and 7 pg ml À 1 for PlGF.
Uterine artery Doppler evaluation
Doppler examination of the uterine arteries was performed using transabdominal ultrasound with color flow mapping. A mid-sagittal view of the uterus was obtained, and the cervical canal was identified. The transducer was then rotated until the paracervical vessels were visualized. The uterine artery was isolated and the PI measured at this point. The mean PI of the measurements in each of the two uterine arteries was calculated and used for analysis. All participating sonographers are certified by the Fetal Medicine Foundation for first-trimester screening.
Statistical analysis
The serum levels for the cases and the control groups were compared using Student's t-test, Mann-Whitney U test, Chi-squared, or Fischer's exact test, as appropriate. The data were tested for normal distribution using Kolmogorov-Smirnov test. Logistic regression modeling was used to estimate the association between each analyte and PE, adjusting for possible confounders identified from the univariate analysis. Receiveroperating characteristic curves and the area under the curves (AUC) were derived from the regression models for each serum analyte. We planned a priori to create a final model to estimate the impact of combining all significant analytes on the prediction of PE. The same analysis was performed for the subgroup of cases with early onset PE requiring delivery at o34 weeks gestation (early PE) and the group with both PE and small for gestational age (SGA) neonates defined as birth weight below the tenth percentile using Alexander's growth chart 16 compared with the control group. A P-value o0.05 was considered significant for all analyses. Statistical analyses were performed using STATA version 10.0 (Stata Corp., College Station, TX).
RESULTS
The demographic and pregnancy characteristics of the cases and the control are shown in Table 1 . The significant differences were a higher body mass index (BMI), lower gestational age at delivery, and lower median birthweight in the cases compared with the control group. In addition, there were more cases among AfricanAmerican women and those with pregestational diabetes and chronic hypertension compared with the controls.
We first sought to determine whether sFlt-1, VEGF, or PlGF levels in maternal serum correlated with any of the known PE risk factors in the controls. Multiple regression analysis in the unaffected group revealed that sFlt-1 level was significantly associated with maternal BMI (beta coefficient À 24.9; P ¼ 0.006) but not with maternal age (beta coefficient À 11.2; P ¼ 0.35), race (beta coefficient À 1.7; 0.97), or smoking status (beta coefficient 324.9; P ¼ 0.20). Regressed free-VEGF levels in the unaffected group were significantly associated with maternal BMI (beta coefficient 0.6; P ¼ 0.032) and age (beta coefficient À 0.9; P ¼ 0.012) but not with race (beta coefficient À 0.2; P ¼ 0.89) or smoking status (beta coefficient À 4.2; P ¼ 0.58). The regressed PlGF levels in the unaffected group were significantly associated with maternal age (beta coefficient À 0.9; P ¼ 0.023), race (beta coefficient À 3.9; P ¼ 0.006), and smoking status (beta coefficient 21.1; P ¼ 0.014) but not with BMI (beta coefficient À 0.4; P ¼ 0.234). There were no significant associations in the controls between mean uterine artery PI and sFlt-1 (P ¼ 0.85), free-VEGF (P ¼ 0.71), or PlGF (P ¼ 0.95).
We next compared values for individual first-trimester maternal serum factors and uterine PI between the controls and the cases of PE, early PE, and PE with SGA. The median and interquartile ranges are depicted in Figure 1 and detailed in Table 2 . Free-VEGF levels were below the detectable range in 87/252 (34.5%) of the controls and in 18/63 (28.6%) of those who developed PE. If those with undetectable free-VEGF levels are included, the median drops to 1.5 with an interquartile range of 22.1. The mean free-VEGF level was significantly higher in the PE group (29.7 versus 16.6 pg ml À 1 , P ¼ 0.04) compared with the control group. The mean PlGF concentration was significantly lower in the group with PE compared with the unaffected control group (33.7 versus 41.1 pg ml À 1 , P ¼ 0.01). The sFlt-1 levels, sFlt-1:PlGF ratios, and PIs were not different between any of the groups.
To assess the relationship between the angiogenic factors or PI and the different categories of PE, we used logistic regression to determine odds ratios (Table 3) . We adjusted these by BMI, First-trimester angiogenic factors and prediction of preeclampsia AO Odibo et al maternal age, race, or smoking as appropriate based on the bivariate analysis described above. The only significant finding was an association between low PlGF level (in the first quartile) and the group with PE and SGA. Receiver-operating characteristic curves revealed that none of the factors were clinically useful for prediction in the first trimester of PE. The AUC and the sensitivity at a fixed false-positive rate of 10% for prediction of PE by the angiogenic factors are: 0.72 for sFlt-1 in the fourth quartile (sensitivity 40%); 0.73 for free-VEGF in the fourth quartile (sensitivity 45%); 0.72 for free-VEGF in the lowest quartile (sensitivity 40%); 0.64 for PlGF in the first quartile (sensitivity 26%); 0.74 for sFlt-1:PlGF ratio in the fourth quartile (sensitivity 40%); and 0.54 for uterine artery PI in the fourth quartile (sensitivity 15%). The findings for all analyses involving free-VEGF were similar when those with undetectable levels were included (data available from authors). An example of the receiveroperating characteristic curve for the prediction of PE by sFlt-1:PlGF ratio is shown in Figure 2 .
DISCUSSION
Here we report that there were significant differences in the firsttrimester levels of two serum angiogenic factors between those destined to develop PE and the control group, but we found no clinically useful first-trimester predictor of PE. There was no significant difference in levels of sFlt-1, but the mean concentration of free-VEGF was higher, and PlGF concentration was lower, in those who later developed PE compared with the control group. Nevertheless, these angiogenic factors were not significantly associated with PE; the only exception was a significant association between low PlGF levels in the group with both PE and SGA. We also found no association between first-trimester uterine artery Doppler and the angiogenic factors evaluated. In addition, the uterine artery PI was not significantly associated with PE in this cohort.
The findings from this study validate previous studies that found no association between first-trimester concentration of sFlt-1 and PE. 5, 9, 17, 18 Such findings are consistent with the Abbreviations: IQR, interquartile range; PI, pulsatility index; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1; SGA, small for gestational age; VEGF, vascular endothelial growth factor. a Excluding subjects with undetectable levels; medians not significantly different from the control at Po0.05.
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A surprising finding from this study was the higher concentrations of free-VEGF levels in those who later developed PE compared with the control group. Although the majority of studies on the association between free-VEGF concentration and PE have reported lower VEGF concentrations in cases who later developed PE, 3, 9, 19, 20 the finding from our study may illustrate the technical difficulties with quantifying this analyte in the first trimester. This idea is supported by both our observation and that of Akolekar et al. 5 that VEGF is frequently below the limit of detection in both cases and controls due to assay problems.
Our findings of high VEGF and no significant difference in sFlt-1 between cases and controls are at odds with a model linking an imbalance in these angiogenic factors with impaired trophoblastic invasion in the pathogenesis of PE. Another hypothesis that has been suggested is that sFlt1 increases in particular regions of the placenta and interferes with local trophoblast migration and vasculogenesis, but these changes are not reflected in circulating sFlt-1 levels during the first trimester of pregnancy. 5 who also detected no association between uterine artery Doppler and sFlt-1, free-VEGF, or PlGF levels. Our results differ in that they reported a high uterine artery Doppler PI in those who developed PE; 5 however, these authors used uterine artery PI converted to multiples of the medians. In this study, we did not convert the uterine artery PI to multiples of the median, as the median concentrations of the cases and control were not significantly different.
The prediction models evaluating the prediction of the different angiogenic markers and different categories of PE did not reveal any reliable analytes with good discriminatory value to be useful clinically. The AUC varied from 0.54 to 0.74 for each threshold of analytes and uterine artery Doppler evaluated. Although those with AUC 40.70 would be considered as a modest discriminatory value, the sensitivity were all o50% for a fixed false-positive rate of 10%. The two other studies that have focused on the role of these angiogenic factors in first trimester in predicting PE did not provide data on their screening performance in comparison to the current study. 5, 17 The limitations of the current study include the case-control design and the small number of cases with early-onset PE. In addition, it is important to note that although several reports have found low PlGF to be a useful predictor of PE, 21, 22 in this study we used a different assay technique to evaluate the PlGF concentrations and this could potentially account for the difference with other studies. There was, however, a significant association between low PlGF and the subgroup of preeclamptics who also have SGA as a complication. We are currently evaluating the impact of using different assays on the findings with this particular serum marker (PlGF) in this patient cohort. In addition, given the small number of cases with early PE (n ¼ 14), our study was underpowered to fully evaluate this subgroup of PE. Finally, unlike the recent report by Coolman et al., 18 we did not evaluate the relationship between a high concentration of sFlt-1 and placental weight or birth weight.
In conclusion, although we found significant differences in firsttrimester serum concentrations of some of the angiogenic factors evaluated, neither these factors nor PI were clinically useful for prediction in women who later developed PE. Figure 2 . Receiver-operating characteristic (ROC) curve for prediction of preeclampsia by sFlt-1:PlGF (soluble fms-like tyrosine kinase-1/placental growth factor) ratio in the fourth quartile.
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